Loading…
PharmaCyte Biotech, Inc. is projected to rise to $1.09 by 2027, a +44% move from its current price of $0.76. PMCB is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $0.721 | $0.7592 | $0.7994 | -0.11% |
| May 30 | $0.705 | $0.7584 | $0.8157 | -0.21% |
| May 31 | $0.6928 | $0.7576 | $0.8283 | -0.32% |
| Jun 1 | $0.6826 | $0.7568 | $0.839 | -0.43% |
| Jun 2 | $0.6736 | $0.7559 | $0.8483 | -0.53% |
| Jun 3 | $0.6655 | $0.7551 | $0.8568 | -0.64% |
| Jun 4 | $0.6581 | $0.7543 | $0.8646 | -0.75% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.6581 | $0.7543 | $0.8646 | -0.75% |
| Week 2 | $0.6173 | $0.7487 | $0.908 | -1.49% |
| Week 3 | $0.5867 | $0.7431 | $0.9412 | -2.22% |
| Week 4 | $0.5614 | $0.7376 | $0.9689 | -2.95% |
| Week 5 | $0.5396 | $0.732 | $0.9932 | -3.68% |
| Week 6 | $0.5202 | $0.7266 | $1.01 | -4.40% |
| Week 7 | $0.5027 | $0.7212 | $1.03 | -5.11% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
PharmaCyte Biotech, Inc. is a biotechnology company in the Healthcare sector focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. Its Cell-in-a-Box platform uses a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various cancers, including advanced and inoperable pancreatic cancer.
It also develops CypCaps for pancreatic cancer and other solid cancerous tumors.
PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada. It has collaboration and license agreements with Iroquois Master Fund Ltd.; SG Austria Pte.
Ltd.; and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc.
in January 2015.
PharmaCyte Biotech, Inc. (PMCB) is a biotechnology company focused on cancer therapies via the Cell-in-a-Box platform. The stock trades at $0.81 per share and has a market capitalization of $8.7M, ranking 5187 by market cap.
The price outlook shows potential upside in the coming years, with a 2026 forecast average of $0.81, rising through 2027 to $1.20 and 2030 to $1.37, and an long-range view culminating in a 2050 average of $4.45 and a max of $10.23. The implied return grows across the horizon, with a 2050 forecasted ROI of 449% and bullish sentiment from 2027 onward.
A major floor 28.1% below — a decisive break under it would weaken the trend.
The nearest floor, 8.6% below — buyers have tended to step in here.
The nearest ceiling, 25.1% above — a clean break opens room to run.
A major ceiling 39.1% above — clearing it would confirm fresh momentum.
Key PMCB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PMCB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.784 | Sell | $0.7797 | Sell |
| MA 10 | $0.7979 | Sell | $0.782 | Sell |
| MA 20 | $0.7755 | Sell | $0.7747 | Sell |
| MA 50 | $0.741 | Buy | $0.7582 | Buy |
| MA 100 | $0.7585 | Buy | $0.776 | Sell |
| MA 200 | $0.8425 | Sell | $0.8714 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 49.17 | Neutral |
| Stoch RSI (14) | 20.96 | Neutral |
| CCI (20) | -29.96 | Neutral |
| Williams %R (14) | -74.54 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | 0.56 | Buy |
| Bollinger %B (20,2) | 0.42 | Neutral |
| Stochastic %K (14) | 25.46 | Neutral |
| TRIX (15) | 0.32 | Buy |
| Awesome (5,34) | 0.03 | Buy |
| Ultimate (7,14,28) | 43.70 | Neutral |
| Momentum (10) | -0.03 | Sell |
| Aroon Osc (25) | 12.00 | Buy |
| Hull MA (9) | 0.79 | Sell |
| ADX (14) | 8.48 | Neutral |
| ATR (14) | 0.04 | Info |
The 30-day technical picture is NEUTRAL. RSI14 is 50, with a 50-day SMA of $0.7379 and a 200-day SMA of $0.8432. The stock has traded within a 30-day range of $0.5669 to $1.16.
Near-term support sits at $0.684 and resistance at $0.9506, defining the upper and lower bounds for the next weeks.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.6507 | $0.76 | $1.09 | 0% | Neutral | |
| $0.791 | $1.09 | $1.63 | +44% | Bullish | |
| $0.7623 | $1.11 | $1.76 | +46% | Bullish | |
| $0.7603 | $1.17 | $1.93 | +53% | Bullish | |
| $0.7794 | $1.25 | $2.15 | +64% | Bullish | |
| $0.5844 | $0.9772 | $1.74 | +29% | Bullish | |
| $0.5989 | $1.04 | $1.91 | +37% | Bullish | |
| $0.7459 | $1.35 | $2.54 | +77% | Bullish | |
| $0.818 | $1.53 | $2.96 | +102% | Bullish | |
| $0.9361 | $1.82 | $3.60 | +140% | Bullish | |
| $0.8207 | $1.82 | $3.95 | +140% | Bullish | |
| $1.71 | $3.80 | $8.74 | +400% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.6507 | $0.76 | $0.9055 | +0.00% |
| June 2026 | $0.6254 | $0.7489 | $0.9285 | -1.46% |
| July 2026 | $0.5663 | $0.6893 | $0.8758 | -7.95% |
| August 2026 | $0.5739 | $0.7075 | $0.9158 | +2.64% |
| September 2026 | $0.6149 | $0.7662 | $1.01 | +8.30% |
| October 2026 | $0.6008 | $0.756 | $1.01 | -1.33% |
| November 2026 | $0.5835 | $0.7407 | $0.9984 | -2.02% |
| December 2026 | $0.623 | $0.7975 | $1.09 | +7.66% |
Click any year to see its month-by-month PMCB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The PMCB price prediction for 2026 points to an average of $0.76 (low $0.6507, high $1.09) — a potential gain of 0% on today's $0.76. A consolidation phase looks the most probable path here.
In 2027, PMCB is projected to trade between $0.791 and $1.63, averaging $1.09 — a potential gain of +44% from today's $0.76. That is up +44% on the projected 2026 average. Momentum favours further upside here.
PharmaCyte Biotech, Inc.'s 2028 outlook centres on $1.11, within a $0.7623 to $1.76 range. That is up +2% on the projected 2027 average. That marks a +46% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, PMCB could reach as high as $1.93, with a base case around $1.17 and support toward $0.7603 — roughly +53% from $0.76. Momentum favours further upside here.
Expect PMCB to range from $0.7794 to $2.15 through 2030. The $1.25 average target implies a +64% move from current prices. That is up +7% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The PMCB price prediction for 2031 points to an average of $0.9772 (low $0.5844, high $1.74) — a potential gain of +29% on today's $0.76. Momentum favours further upside here.
In 2032, PMCB is projected to trade between $0.5989 and $1.91, averaging $1.04 — a potential gain of +37% from today's $0.76. That is up +7% on the projected 2031 average. Buyers look set to stay in control over this stretch.
PharmaCyte Biotech, Inc.'s 2033 outlook centres on $1.35, within a $0.7459 to $2.54 range. That is up +29% on the projected 2032 average. That marks a +77% change versus current levels. Momentum favours further upside here.
By 2034, PMCB could reach as high as $2.96, with a base case around $1.53 and support toward $0.818 — roughly +102% from $0.76. Buyers look set to stay in control over this stretch.
Expect PMCB to range from $0.9361 to $3.60 through 2035. The $1.82 average target implies a +140% move from current prices. That is up +19% on the projected 2034 average. Momentum favours further upside here.
The PMCB price prediction for 2040 points to an average of $1.82 (low $0.8207, high $3.95) — a potential gain of +140% on today's $0.76. Buyers look set to stay in control over this stretch.
In 2050, PMCB is projected to trade between $1.71 and $8.74, averaging $3.80 — a potential gain of +400% from today's $0.76. That is up +108% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in PMCB today (≈ 1,315.789474 PMCB) could be worth
$5,000.93
+$4,000.93 (+400%) by 2050 · US Dollar
Based on the average projected PMCB price of $3.8 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PMCBwould be worth at today's price.
$1,000 invested in PMCB on May 27, 2025 (≈ 989.902966 PMCB) would be worth
$752.33
-$247.67 (-24.8%) today · 0.75× · US Dollar
Based on a PMCB entry price of $1.01 vs. today's $0.76.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.7682 | $989.33 | -1.1% |
| 1 month ago | $0.7627 | $996.46 | -0.4% |
| 3 months ago | $0.704 | $1,079.55 | +8.0% |
| 6 months ago | $0.7736 | $982.42 | -1.8% |
| 1 year ago | $1.01 | $752.33 | -24.8% |
| All time (5.0y) ago | $20 | $38.01 | -96.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PMCB forecast.
Our base-case forecast reaches $1.50 around 2034.
Implied market cap at $1.50: $16.1M
The multi-year forecast paints a bullish path after 2026. In 2026 the average price is forecast at $0.81 with a min of $0.6507 and a max of $1.20, and an ROI of 0, indicating neutral sentiment for that year. From 2027 onward, the average price grows to $1.20 (2027), $1.23 (2028), $1.30 (2029), and $1.37 (2030), with corresponding max values and ROIs up to 69.1.
In 2031 the average is $1.07 with a max of $1.93 and ROI 31.8; 2032 average $1.17, max $2.18, ROI 44.7; 2033 average $1.55, max $2.96, ROI 91.2; 2034 average $1.77, max $3.46, ROI 118.3; 2035 average $2.09, max $4.19, ROI 158.3. By 2040 the average is $2.15 with a max of $4.73 and ROI 165.6; by 2050 the average reaches $4.45 with a max of $10.23 and ROI 449. The sentiment remains BULLISH across these years.
These figures imply a steady ascent in the price trajectory, but they are estimates, not guarantees, and actual performance can vary. The main caveat is that this asset operates with a small market cap and earlier-stage clinical outcomes may impact realized prices.
Tap a question to reveal the answer.
The forecast for 2030 shows an average price of $1.37 per share, with a min of $0.8415 and a max of $2.39, and an ROI of 69.1; sentiment is BULLISH.
Forecasts show a bullish path after 2026, with the average price rising to $4.45 by 2050 and a max of $10.23, implying a potential ROI up to 449% by 2050. However, the 2026 year is neutral and these are estimates, not guarantees.
Yes. The 2050 forecast lists a max price of $10.23 and an average of $4.45, with a 2050 ROI of 449%, indicating it can exceed $2.00 well before 2050 and reach higher prices according to the forecast.
RSI14 is 50, SMA50 is $0.7379, SMA200 is $0.8432, and the stock trades within the 30-day price range of $0.5669 to $1.16.
The current price is $0.81 per share and the market cap is $8.7M, with a rank of 5187 by market cap.
PharmaCyte Biotech, Inc. Community Discussion
0Share your PharmaCyte Biotech, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.